Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q3 2023 Earnings Presentation

14 slides from Abcellera Biologics's earnings presentation, Nov 2, 2023

1. Slide 1: Q3 2023 Business Update

   Q35 2023 BUSINESS UPDATE NOVEMBER 2, 2023

2. Slide 2: Disclaimer

   Q3 2023 BUSINESS UPDATE ry DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements. are based on management's beliefs and assumptions and

3. Slide 3: Q3 2023 Business Update Summary

   Q3 2023 BUSINESS UPDATE Q3 2023. BUSINESS UPDATE SUMMARY. Continued focus SB13M iissons on high-value 182 ennsnssom programs & strategic 110 epee partnerships 1

4. Slide 4: Programs

   Q3 2023 BUSINESS UPDATE PROGRAMS Two AbCellera-led programs advancing into IND-enabling studies. MOLECULE TARGET ABCL575 OX40L INDICATION atopic dermatitis THERAPEUTIC POTENTIAL AREA DIFFERENTIATION immunology and A best in class inflammation POTENTIAL MARKET SIZE $17B by 2032* ABCL635 undisclosed G

5. Slide 5: Partnerships

   Q3 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA PARTNERSHIPS Strategic collaborations with new and existing partners. REGENERON (Incyte) programs under contract 4 new 2 completed Regeneron has exercised its rights to advance antibody candidates into further Q MULTIPLE INDICATIONS preclinical developme

6. Slide 6: Priorities

   Q3 2023 BUSINESS UPDATE PRIORITIES Delivering on stated business objectives. ELECT EXECUTE candidates for strategic IND-enabling studies partnerships ADVANCE T-cell engager platform

7. Slide 7: Q3 Financials

   Q35 2023

8. Slide 8: Continuing portfolio growth

   Continuing portfolio growth. Cumulative # of Cumulative # of Partnered Program Starts Molecules in the Clinic 7 = = = = 110 10 D no 10 ra 100 9 = Total # of 90 8 2 80 7 = Programs Under Contract 182 70 6 SS 60 5 ie 50 o Total # of 40 “ 30 3 Discovery Partners 20 2 °m 0 2015 16 17 18 19 20 21 22 23 2

9. Slide 9: New molecules in the clinic

   n i%) ry z a = ) m nN o nN Oa) o Now 10 molecules in the clinic. MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab Marketed, Emergency Use . . (LY.CoVS85) Authorization (EVA) infectious disease: COVID-19 AbCellera-initiated program PARTNERED bebtelovimab Marketed, Emergency Use . . (

10. Slide 10: $7M total revenue, predominantly from discovery activity

    $7M total revenue, predominantly from discovery activity. $101.4M Revenue USD m ROYALTIES O MILESTONES LICENSING M@ RESEARCH FEES wu = =x a a —) n i%) ry z a = ) m nN o nN Oa) o Q3 2022 Q3 2023

11. Slide 11: Operating expenses reflect ongoing investments, predominantly in R&D

    Operating expenses reflect ongoing investments, predominantly in R&D. Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN wu = =x a a —) n i%) ry z a = ) m nN o nN Oa) o $26.6M $3.1M $3.5M | Sz, = [1 Q3 2022 Q3 2023 Q3 2022 Q3 2023 Q3 2022 Q3 2023

12. Slide 12: Net loss of $29M; equivalent to ($0.10) per share

    wu = =x a a —) n i%) ry z a = ) m nN o nN Oa) o Net loss of $29M; equivalent to ($0.10) per share (basic ¢ diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED $26.6M $0.09 $0.08 -$28.6M -$0.10 -$0.10 Q3 2022 Q3 2023 Q3 2022 Q3 2023 Q3 2022 Q3 2023

13. Slide 13: Over $800M in total cash, equivalents, and marketable securities

    wu = =x a a —) n i%) ry z a = ) m nN o nN Oa) o Over $800M in total cash, equivalents, and marketable securities. Cash Flows USD $915M $500M Marketable Securities $102M Marketable Securities (net) ($24M) $387M $95M Cash & Other Equivalents ($197M) $613M Marketable Securities SoM $172M Cash & Equival

14. Slide 14: Thank You

AbCellera Biologics — Q3 2023 Earnings Presentation on 6ix